Natalia Geyvandova

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

W. Haefeli, M. Haag, U. Merle, 2022, The Lancet. Infectious diseases.

Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.

K. Reddy, M. Shiffman, S. Harrison, 2010, Gastroenterology.

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

A. Berger, S. Ciesek, P. Lampertico, 2023, The New England journal of medicine.

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2022, Journal of Hepatology.

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

M. Buti, M. Biermer, T. Asselah, 2023, The Lancet Gastroenterology & Hepatology.

[The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].

N. Pogosova, M. Shestakova, I. Nikitin, 2022, Terapevticheskii arkhiv.